Literature DB >> 16132278

Beraprost therapy in children with pulmonary hypertension secondary to congenital heart disease.

A Limsuwan1, P Pienvichit, P Khowsathit.   

Abstract

We present a report on children with severe pulmonary hypertension secondary to congenital heart disease who received 6 months of beraprost therapy. The children had an increase in intracardiac left-to-right shunt and a reduction of the pulmonary-to-systemic vascular resistance ratio, whereas the pulmonary artery pressure was not significantly changed.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16132278     DOI： 10.1007/s00246-005-0925-4

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN： 0172-0643            Impact factor:   1.655


  26 in total

1.  Sildenafil for pulmonary arterial hypertension: still waiting for evidence.

Authors:  Marc Humbert; Gérald Simonneau
Journal:  Am J Respir Crit Care Med       Date:  2004-01-01       Impact factor: 21.405

2.  Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: a case series.

Authors:  V V McLaughlin; D E Genthner; M M Panella; D M Hess; S Rich
Journal:  Ann Intern Med       Date:  1999-05-04       Impact factor: 25.391

3.  Short-term hemodynamic effect of a new oral PGI2 analogue, beraprost, in primary and secondary pulmonary hypertension.

Authors:  T Saji; Y Ozawa; T Ishikita; H Matsuura; N Matsuo
Journal:  Am J Cardiol       Date:  1996-07-15       Impact factor: 2.778

4.  Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension.

Authors:  Robyn J Barst; Dunbar Ivy; Jasper Dingemanse; Allison Widlitz; Kelly Schmitt; Aimee Doran; Deborah Bingaman; Ngoc Nguyen; Michael Gaitonde; Paul L M van Giersbergen
Journal:  Clin Pharmacol Ther       Date:  2003-04       Impact factor: 6.875

5.  Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension.

Authors:  V V McLaughlin; D E Genthner; M M Panella; S Rich
Journal:  N Engl J Med       Date:  1998-01-29       Impact factor: 91.245

6.  Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension.

Authors:  N Nagaya; M Uematsu; Y Okano; T Satoh; S Kyotani; F Sakamaki; N Nakanishi; K Miyatake; T Kunieda
Journal:  J Am Coll Cardiol       Date:  1999-10       Impact factor: 24.094

7.  Acute effect of oral prostacyclin and inhaled nitric oxide on pulmonary hypertension in children.

Authors:  F Ichida; K Uese; I Hashimoto; Y Hamamichi; S Tsubata; K Fukahara; A Murakami; T Miyawaki
Journal:  J Cardiol       Date:  1997-04       Impact factor: 3.159

8.  Initial experience with bosentan therapy in patients with the Eisenmenger syndrome.

Authors:  Douglas D Christensen; Michael E McConnell; Wendy M Book; William T Mahle
Journal:  Am J Cardiol       Date:  2004-07-15       Impact factor: 2.778

9.  The use of oxygen and prostacyclin as pulmonary vasodilators in congenital heart disease.

Authors:  A Bush; C M Busst; E A Shinebourne
Journal:  Int J Cardiol       Date:  1985-11       Impact factor: 4.164

10.  Beraprost therapy for pulmonary arterial hypertension.

Authors:  Robyn J Barst; Michael McGoon; Vallerie McLaughlin; Victor Tapson; Stuart Rich; Lewis Rubin; Karlman Wasserman; Ronald Oudiz; Shelley Shapiro; Ivan M Robbins; Richard Channick; David Badesch; Barry K Rayburn; Robin Flinchbaugh; Jeff Sigman; Carl Arneson; Roger Jeffs
Journal:  J Am Coll Cardiol       Date:  2003-06-18       Impact factor: 24.094
View more
  5 in total

Review 1.  Pulmonary hypertension complicating congenital heart disease.

Authors:  J Eduardo Rame
Journal:  Curr Cardiol Rep       Date:  2009-07       Impact factor: 2.931

Review 2.  Advances in diagnosis and treatment of pulmonary arterial hypertension in neonates and children with congenital heart disease.

Authors:  Monnipa Suesaowalak; John P Cleary; Anthony C Chang
Journal:  World J Pediatr       Date:  2010-02-09       Impact factor: 2.764

Review 3.  Pharmacologic strategies in neonatal pulmonary hypertension other than nitric oxide.

Authors:  Satyan Lakshminrusimha; Bobby Mathew; Corinne L Leach
Journal:  Semin Perinatol       Date:  2016-01-14       Impact factor: 3.300

Review 4.  Pediatric pulmonary arterial hypertension.

Authors:  Dan-Chen Wu; Hong-Da Zhang; Zhi-Cheng Jing
Journal:  Curr Hypertens Rep       Date:  2013-12       Impact factor: 5.369

5.  Pulmonary vasodilator therapy in persistent pulmonary hypertension of the newborn.

Authors:  T J Kulik; J E Lock
Journal:  Clin Perinatol       Date:  1984-10       Impact factor: 3.430
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.